Buparvaquone Powder

Get a Price/Quote

MOQ : 50 Kilograms

Buparvaquone Powder Specification

Shelf Life
12 Months

Smell
No Smell

Purity(%)
100%

Physical Form
Powder

Buparvaquone Powder Trade Information

Minimum Order Quantity
50 Kilograms

Payment Terms
Cash Advance (CA), Cash in Advance (CID)

Supply Ability
1000 Kilograms Per Day

Delivery Time
7 Days

Main Export Market(s)
Western Europe, Australia, Central America, Middle East, South America, Asia, Eastern Europe, North America, Africa

About Buparvaquone Powder

Our company, Shreeji Pharma International, is a leading manufacturer of buparvaquone in Gujarat. India. WeThe professionals manufacture products under a GMP site with full regulatory support. It is a hydroxynaphthoquinone antiprotozoal similar to parvaquone and atovaquone. It is a promising compound for the therapy and prophylaxis of all kinds of theileriosis. It has been shown that buparvaquone has anti-leishmanial activity in vitro. As of today, Shreeji Pharma International exports Buparvaquone to countries in the Gulf, South East Asia, Africa, CIS, LATAM, Central America and Europe.

Properties:

Name: Buparvaquone
CAS No.: 88426-33-9
Formula: C₂₁H₂₆O₃
Molecular Weight: 326.43
Synonyms: 2-((4-tert-Butylcyclohexyl)methyl)-3-hydroxy-1,4-naphthochinon;1,4-Naphthalenedione, 2-((4-(1,1-dimethylethyl)cyclohexyl)methyl)-3-hydroxy-;Buparvaquone [BAN:INN];4-hydroxy-3-[(4-tert-butylcyclohexyl)methyl]naphthalene-1,2-dione;Buparvacuona [Spanish];Butalex;BW 720C; 2-((4-(1,1-Dimethylethyl)cyclohexyl)methyl)-3-hydroxy-1,4-naphthalenedione;2-((4-tert-Butylcyclohexyl)methyl)-3-hydroxy-1,4-naphthoquinone;(RS,RS,RS,RS)-2-((4-tert-Butylcyclohexyl)methyl)-3-hydroxy-1,4-naphthoquinone;Buparvaquonum [Latin];
Density: 1.158 g/cm3
Melting Point: 178-184 °C
Boiling Point: 460.687 °C at 760 mmHg
Flash Point: 246.536 °C
Appearance: Yellow crystalline solid

How does it work?

It is currently being evaluated for use in treatment and prophylaxis of theileriosis. In vitro, buparvaquone is anti-leishmanial. Along with other known substances, it can treat bovine East Coast fever protozoa in vitro.

Manufacturing process:

A preparation method for buparvaquone is disclosed in the invention, which relates to medicine synthesis. Preparation involves: starting with 1,4-benzopyran diketone and p-tert-butylcyclohexyl acetaldehyde, then performing condensation and rearrangement to produce pharmaceutical grade buparvaquone. Buparvaquone can be prepared using the invention without using an expensive catalyst, and its synthesis yield is increased by approximately 65% compared to prior art. Additionally, the route is environment-friendly and industrially feasible.

How to use:

A veterinarian should administer injections of buparvaquone into the neck muscles. If it is severe, the treatment can be repeated every 48 to 72 hours. At the injection site, administer only 10 ml per injection.